Daniel Bloomfield, MD

About

Daniel Bloomfield, MD, M.Phil is a Partner at Ascenta Capital. He has held leadership roles in the pharmaceutical and biotech industry for more than 20 years and has broad experience all phases of drug development with a focus on both early and late clinical development. Most recently, Dan was the Chief Medical Officer of Anthos Therapeutics which was developing abelacaimb, a Factor XII/Xia inhibitor, that is currently in Phase 3. In April of 2025, Anthos was acquired by Novartis and Dan continues to be engaged in the development of abelacimab. Prior to joining Anthos, Dan helped create Cardurion Pharmaceutical in May 2017 as its first Chief Executive Officer and remains a senior advisor.

Source (opens in a new tab)